DiaMedica Therapeutics’ (DMAC) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

Separately, Oppenheimer restated an “outperform” rating and set a $6.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, August 16th.

DiaMedica Therapeutics Stock Up 3.5 %

NASDAQ DMAC opened at $4.15 on Friday. The company has a 50-day simple moving average of $4.30 and a two-hundred day simple moving average of $3.59. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $4.95. The firm has a market cap of $177.46 million, a price-to-earnings ratio of -7.41 and a beta of 1.46.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of DiaMedica Therapeutics by 26.3% in the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after purchasing an additional 211,351 shares during the last quarter. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the 2nd quarter worth approximately $87,000. Blue Trust Inc. purchased a new position in shares of DiaMedica Therapeutics during the third quarter valued at approximately $185,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of DiaMedica Therapeutics during the third quarter valued at approximately $40,000. Finally, Geode Capital Management LLC lifted its stake in DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after acquiring an additional 70,070 shares during the period. 10.12% of the stock is owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.